In 1991 we reported the results from a prospective randomised national phase 3 trial in which the effects of induction therapy phase 3 trial comparing 7 days continuous infusion of cytosine with the anthracycline aclarubicin (ACR) were compared with arabinoside (ara-C) combined with either daunorubicin (DNR) daunorubicin (DNR), each in combination with cytosine araor aclarubicin (ACR) as direct i.v. injection for 3 days as inducbinoside (ara-C) in a 3 + 7 regimen. This was followed by early tion chemotherapy (CT) for patients with de novo acute myeloid intensive post-remission consolidation CT with four alternatleukemia (AML) followed by early intensive consolidation CT with two alternating cycles of high-dose ara-C and two cycles ing cycles of high-dose ara-C and amsacrine plus etoposide of amsacrine plus etoposide, and finally 3 days of daunomycin followed by a final course of the 3 + 7 regimen with DNR. 
group (51%) for the age group 17-60 years. Age of the patient till death or for at least 7 years, and an evaluation of the longwas the most important prognostic factor for achieving comterm survival and the risk of developing secondary neoplasms has been made. The overall survival rate 5-years after diagplete remission, for remission duration and for survival.
nosis was 23%, and after 10 years 19%. No difference was
Among younger patients (17-39 years), the projected survival found between the two treatment regimens in overall survival rate 4 years after diagnosis was relatively high, 41%. In series or disease-free survival (DFS). For the subgroup of 99 patients of patients treated with intensive CT followed by allogeneic who achieved complete remission after one or two induction bone marrow transplantation, secondary malignancies, particourses, 5-and 10-year survival rates were 35% and 31% cularly solid tumors and lymphomas, are reported with a risk respectively, with the highest survival rates in the age group 17-39 years (57% at 5 years) as compared with 27% in patients of six to seven times the risk in the normal population. 9 As aged 40-60 years (P = 0.007). Seven secondary neoplasms only a few studies of long-term survival in intensively treated were diagnosed simultaneously with or after the diagnosis of AML patients have been published, 3, 5, [10] [11] [12] and as other sec- A total of 174 consecutive previously untreated patients in the age-group 17-65 years with de novo AML diagnosed in the Introduction period 1984-1987 in Denmark were considered eligible for randomization in the trial. Patients with pre-existing liver or Anthracycline and cytosine arabinoside induction therapy for heart disease or renal impairment of WHO grades 3-4 unrepreviously untreated de novo AML in adults is one of the most lated to the leukemia or any major psychiatric illness were widely used regimens and produces complete remission (CR) not included. rates of 60-80% in most studies. [1] [2] [3] [4] [5] [6] [7] However, a high percentage of the patients suffer from relapse, even in series with intensive post-remission consolidation chemotherapy. In the cycline dose was reduced by 33% for patients over 60 years of age. If CR was not achieved after the first course, a second 95% confidence intervals were calculated assuming a Poisson distribution. 2 days of treatment with either DNR or ACR and a 5-day course of ara-C was administered. Patients achieving CR after Duration of remission was calculated from the date of CR until relapse or censored on last day seen in CR. Survival was one or two induction courses continued with consolidation treatment (n = 99). Patients who did not achieve CR were conmeasured from diagnosis until death or, if alive, censored on the last date seen alive. Nine patients (ACR = 8; DNR = 1), sidered treatment failures and removed from the study but included in the analysis of the overall survival.
AML indicating a standardized incidence ratio (SIR
who subsequently entered allogeneic bone marrow transplantation, all except one in у2 remission, were censored from analysis of remission duration at the date of transplantation. All patients alive have been followed until 1 January 1995.
Consolidation therapy
Survival status in eight cases was obtained from the Danish Central Population Registry since the patients were no longer Early intensive post-remission consolidation therapy consisted of five courses of CT at 6-week intervals. The first and third available for clinical control at the hospital. The median follow up time was 8.6 years (range 7.0-10.7). courses consisted of high-dose ara-C 3 g/m 2 by 3-h intravenous infusions every 12 h for eight doses (in patients over Analysis of overall survival and disease-free survival (DFS) were performed by the product limit method of Kaplan-60 years of age, six doses). The second and fourth courses consisted of amsacrine, 90 mg/m 2 /day i.v. (patients over 60 Meier. 15 Survival analyses were compared using the log-rank test. Fisher's exact test, the 2 test for trend and the logistic years of age, 60 mg) for 5 days, combined with etoposide, 100 mg/m 2 /day i.v. for 5 days. The fifth and final course conregression analysis were used for analysis of statistical differences. Analyses were performed using the SAS programme.
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sisted of DNR plus ara-C in the 3 + 7 regimen used for induction CT. After the completion of the consolidation courses, which 72% of the patients completed, no further anti-leukemic therapy was administered until an eventual relapse. Results Treatment at relapse was initiated according to performance status. In general, early relapse patients received other regi-
The overall survival for all 174 patients entered in the study is shown in Figure 1 , subdivided according to age: 17-39 mens and patients with late relapse received the initial regimen again. Young patients were referred to allogeneic years, 40-60 years and 61-65 years. As shown in our previous study, age was a predictive factor for both the overall survival bone marrow transplantation.
(P Ͻ 0.001) and the duration of remission (P = 0.011, data not shown) with a higher probability of survival and staying in remission for younger patients. In Figure 2 the overall survival Diagnosis and evaluation of response and duration of remission for the 99 patients achieving CR is shown. Ten patients died in CR while receiving post-remission The classification of AML was performed according to FAB criteria, 13 patients with a history of previous myelodysplasia CT. Five years after diagnosis, the survival probability was 35% vs 27% for staying in remission. After 10 years, the probor other hematological or malignant diseases were not entered in the study. CR was defined as a bone marrow with normal abilities were reduced to 31% and 22%, respectively. The results from survival analyses according to age-group, gender cellularity, normal erythroid and myeloid cells, myeloblasts and promyelocytes not exceeding 5%, normal cell counts in and treatment for all patients and for the patient achieving CR are shown in Table 1 . No significant difference was seen peripheral blood, and a normal performance status. Relapse was defined as a return of leukemic cells in excess of 25% in between the two treatment groups or the two sexes, and a hypercellular bone marrow or the appearance of extramedullary leukemic foci. In patients with 10-24% blasts, repeated bone marrow examination was performed until definition for relapse was fulfilled.
Statistical analysis and follow-up
Information about follow-up and survival status was obtained from all participating centers. Any cases of secondary cancer diagnosed simultaneously with or subsequent to the AML diagnosis were retrieved in the Danish Cancer Registry which receives notification from all clinics and hospitals about patients with cancer. Since 1987 a linkage to the National Hospital Discharge Registry has supplied information on all suspected cancer cases, and by a linkage to the Danish Central Population Registry and the National Death Index, vital status of all cancer patients is obtained. To estimate the relative risk of developing a secondary neoplasm, the expected numbers of cancer according to sex, age and time-specific incidence rates in the Danish population were compiled. The between the observed and the expected number of cases, and neither duration of remission nor overall survival differed sigyears). The estimated expected number of secondary neoplasms in this cohort of patients was 2.05 equivalent to an SIR nificantly between the two treatment groups, also when subgroups were analyzed separately. of 3.41 (95% CI: 1.60-7.26). However, when only the three tumors that could have been influenced by the intensive The hazard rate for relapse according to age-group is shown in Figure 3 . A continuously decreasing rate was seen for chemotherapy given for AML were included in the analysis (Table 2) , the SIR was not significantly increased (SIR = 1.46, patients 60 years or younger reaching 0 after 8 years. In contrast, after an initial decrease a continuous increase in the haz-95% CI: 0.47-4.57). ard rate for patients aged 61-65 years was observed reaching 1.0 at 6 years after the initial diagnosis was made.
Seven secondary tumors were diagnosed at the time of or Discussion after the diagnosis of AML was made (Table 2) . Three tumors were diagnosed simultaneously with the AML diagnosis; a
The objectives of this analysis were to determine the long-term DFS and overall survival for adult patients receiving induction colon carcinoma, a renal carcinoma and a malignant histiocytoma of the lung. Four tumors were diagnosed in the subchemotherapy with either ACR-ara-C or DNR-ara-C followed by early intensive consolidation chemotherapy and, secondly, sequent period; a psammomatous meningeoma diagnosed at autopsy, a nasal carcinoma diagnosed in the same patient to estimate the risk of developing a second malignancy following intensive treatment for AML. with colon carcinoma at AML diagnosis, a prostate carcinoma and a basal cell carcinoma of the skin. The mean age at time
The survival rate decreased from 23% to 19% in the period 5 to 10 years after diagnosis because of six deaths all due to of diagnosis of the solid tumors was 58 years (range 48-67 relapse of AML. Three of the relapsing patients were in the age group compared to patients aged 40-60 years developed group of 37 patients aged 17-60 years (8%), the remaining particularly in the first 2 years after achieving CR due to a three in the age group 61-65 years. Although patients 60 years slightly elevated hazard rate of relapse as seen in Figure 3 . of age or younger who received ACR-ara-C achieved CR more Subsequently no difference in the relapse rate was observed frequently, no favor in the long-term survival rates or DFS was between the two age groups. The relatively high percentage observed for this treatment, confirming our first report. 8 Eight of young patients maintaining a disease-free survival after 5-of the nine patients who underwent bone marrow transplan-10 years from diagnosis compares favorably with the results tation, all in the age group 17-39 years, were still alive at the obtained with autologous or allogeneic bone marrow transend of this follow-up. The inclusion of these patients in the plantation, also when the transplanted patients in this study overall survival analysis increased the survival rates by are censored from the survival analysis. 18, 19 approximately 2% for all ages and 5% for the younger Many reports are available regarding the occurrence of patients.
myelodysplasia and AML following chemotherapy, radioOther studies of long-term survival in de novo AML are therapy and autologous bone marrow/stem cell transplanavailable for comparison. Schiller et al 5 studied 266 patients tation for hematological malignancies and solid tumors. [20] [21] [22] treated with intensive chemotherapy in the period 1982-1991 To our knowledge, no previous study has discussed in more of whom 67% attained CR and the survival probability after detail the occurrence of solid tumors in patients treated for de 5 years for patients achieving CR was 33% compared with novo AML. Witherspoon et al 9 have studied the occurrence of 35% in the present study. Bandini et al 7 reported the longsecondary malignancies among 2246 patients who underwent term results from 156 de novo AML patients under 60 years allogeneic bone marrow transplantation for hematopoietic of age. Sixty per cent achieved CR and the overall survival at malignancies and aplastic anemia. Of these, 35 patients with 7 years was 15% and the corresponding DFS 22%. Preisler et a mean age of 21 years developed a secondary cancer (16 al 10 studied 760 patients from three CALGB protocols. After lymphoma, six leukemia and 13 a solid tumor) 1.5 months-8 years, 16% of the patients were still in remission, slightly 13.9 years after transplantation and a significantly increased lower than the 22% in the present study. In 1991, Bennett et risk of 6.69 was seen the first year after the transplantation al 11 reported the long-term results from two ECOG studies on compared with the normal population. In the present study 545 patients treated during the 1970s who achieved CR and seven solid tumors developed in six of the 174 treated AML were followed from 7.5 to 12 years. The DFS decreased from patients in this cohort. The increased incidence of solid approximately 15% at 5 years to approximately 10% at 10 tumors diagnosed at the same time as the AML diagnosis may years. Although a higher proportion of the patients in this be surprising. However, patients with AML are often carefully study were above 60 years of age compared to the present examined at diagnosis and inadequate and even slight sympstudy, and patients in this age group have a very poor longtoms may result in extensive laboratory and X-ray examinterm survival, as seen in Figures 2 and 3 , the use of a less ations. This probably explains the increased number of solid intensive post-remission treatment schedule is a more probtumors we observed at the time of the AML diagnosis. In conable explanation for the lower rates obtained in this study.
trast to Witherspoon et al 9 we found no increased risk of secFinally Bü chner et al 17 studied 755 patients with AML. ondary neoplasms among younger patients. The increased risk Patients up to 60 years of age were treated with double induction therapy with either TAD/TAD or TAD/HAM leading to a of a solid tumor was definitely not related to the chemo-CR rate of 63% and 5-year survival DFS of 34 ± 6% which is therapy administered for AML but perhaps related to a more somewhat higher than the DFS of 29 ± 10% in the correspondgenerally increased risk of solid tumors in patients with AML ing age group shown in Table 1 . In contrast to the present due to genetic predisposition. study, patients with preceding myelodysplasia were not Our study showed that 27% of the patients 60 years of age excluded indicating that the discrepancy is perhaps even or younger, are still in CR 10 years after diagnosis, but some larger. The use of a more intensive induction therapy is probrelapses still occurred up to 8 years after the initial diagnosis. ably the main reason for the relatively high DFS rate.
Although it seems likely that a plateau in the DFS curve has The general importance of patients' age for survival from been reached, a longer follow-up is necessary to determine AML confirms many previous studies 3, 5, 7 and like these studif patients at this point can be regarded as 'cured' of their ies, we found a marked reduction in the survival rate for pa-AML. tients aged over 60 years and a favorable survival for patients under 40 years of age. The survival advantage in the young 41 acute myelogenous leukemia treated with conventional mainte-
